Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.

Atherosclerosis·2026
Same author

Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial.

The lancet. Diabetes & endocrinology·2026
Same author

Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases.

Molecular metabolism·2025
Same author

Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary.

Future cardiology·2025
Same author

Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.

Circulation·2025
Same author

Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions.

Archives of medical science : AMS·2024

Related Experiment Videos

Do all lupus patients need statins?

Martin Soubrier1, Sylvain Mathieu, Marion Hermet

  • 1Service de rhumatologie, hôpital G.-Montpied, place H.-Dunant, BP 69, 63003 Clermont-Ferrand, France. msoubrier@chu-clermontferrand.fr

Joint Bone Spine
|October 27, 2012
PubMed
Summary
This summary is machine-generated.

Systemic lupus erythematosus (SLE) patients have accelerated atheroma, suggesting statin benefits. However, routine statin therapy is not recommended due to a lack of specific studies in this population.

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is associated with accelerated atheroma.
  • Statin therapy is known to reduce cardiovascular morbidity and mortality.
  • Potential cardiovascular and immunological benefits of statins in SLE patients are suggested.

Purpose of the Study:

  • To evaluate the appropriateness of routine statin therapy in SLE patients.
  • To assess the cardiovascular and immunological effects of statins in SLE.
  • To determine the impact of statins on subclinical atheroma markers in SLE.

Main Methods:

  • Review of existing literature on statin therapy in SLE.
  • Analysis of cardiovascular risk factors and atheroma markers in SLE patients.
  • Evaluation of evidence for immunomodulatory effects of statins in SLE.

Main Results:

  • No large interventional studies specifically on statins in SLE patients exist.
  • The immunomodulatory role of statins in SLE is not convincingly established.
  • The effect of statins on subclinical atheroma markers (intima-media thickness) in SLE is unclear.

Conclusions:

  • Routine statin therapy is not currently recommended for SLE patients due to insufficient evidence.
  • SLE patients should be classified as high cardiovascular risk, requiring annual lipid profile monitoring.
  • Target LDL-cholesterol levels should be <100 mg/dL for high-risk and <70 mg/dL for very high-risk SLE patients, with statins being the primary treatment option.
  • Statin therapy in SLE patients necessitates monitoring of transaminase levels due to comorbidities and polypharmacy.